Scilex Holding Company Announces New Patent for ELYXYB
Scilex has announced that the U.S. Patent and Trademark Office has approved several claims from U.S. patent application no. 17/562,229. This will lead to the issuance of a new patent related to the treatment of acute pain, further bolstering the Company’s intellectual property for its acute migraine treatment drug, ELYXYB®, which is a liquid, micro-encapsulation formulation of celecoxib.
About ELYXYB®
ELYXYB® stands out as a first-line treatment and is the only FDA-approved, ready-to-use oral solution specifically designed for the acute treatment of migraines, with or without aura, in adults. The U.S. market for oral migraine medications is substantial, reflecting a strong need for effective treatment options.
Market Impact of ELYXYB®
As a fast-acting and ready-to-use formulation of Celecoxib, ELYXYB® serves as a non-opioid therapeutic alternative to addictive opioids and acetaminophen, which is associated with acute liver failure cases in the U.S.
Acute Pain Statistics
According to DelveInsight, there were around 100 million instances of acute pain in the U.S., with the overall acute pain market valued at approximately $3 billion.
Clinical Research and Benefits
Recent research provides strong support for the use of non-steroidal anti-inflammatory drugs (NSAIDs) as first-line treatments for migraines. ELYXYB® (celecoxib oral solution) presents a lower incidence of gastrointestinal (GI) side effects compared to other NSAIDs, making it a suitable choice for patients.
Patient Responses to ELYXYB®
In clinical trials, patients taking ELYXYB® reported pain relief within just 15 minutes, with about 50% experiencing significant relief compared to a placebo within 45 minutes.
Management Insights from Scilex
"We are thrilled about ELYXYB® since its launch. This product equips physicians with an effective tool for managing migraines. The new patents open up possibilities for future applications in acute pain management," stated Jaisim Shah, Chief Executive Officer and President of Scilex.
About Scilex Holding Company
Scilex Holding Company is committed to acquiring, developing, and commercializing non-opioid pain management solutions for both acute and chronic pain, focusing on areas with high unmet needs and significant market potential. The company’s commercial portfolio includes notable products such as ZTlido® and Gloperba®.
Company Contact Information
For further inquiries, please reach out to the Company:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Frequently Asked Questions
What is the significance of the new patent for ELYXYB®?
The new patent enhances Scilex’s intellectual property for ELYXYB®, strengthening its position in the migraine treatment market.
How does ELYXYB® work as a migraine treatment?
ELYXYB® is an oral solution that acts swiftly to relieve migraine symptoms, offering a non-opioid alternative to conventional pain relief methods.
What are the potential market benefits of ELYXYB®?
The oral migraine drug market is considerable, indicating a strong demand for effective treatments like ELYXYB® that cater to acute migraine needs.
What other products does Scilex offer?
Besides ELYXYB®, Scilex also provides ZTlido® for neuropathic pain relief and Gloperba® for gout flare prevention.
Where is Scilex headquartered?
Scilex Holding Company is based in Palo Alto, California.
